OsvaRen is indicated for the management of hyperphosphatemia in adults who are living with chronic kidney disease and require dialysis—including both hemodialysis and peritoneal dialysis. Hyperphosphatemia is a condition characterized by high levels of phosphate in the blood, which is a common and serious consequence when the kidneys lose their ability to effectively process minerals. The medicine helps patients support the balance of serum phosphate levels. Its use is focused on addressing the elevated phosphate burden that occurs in this specific patient population. By assisting in the maintenance of this mineral balance, OsvaRen supports the overall therapeutic strategy for managing chronic kidney disease-related complications.

Quick Fact: Relief for High Phosphate Levels in Dialysis Patients

Who Can and Cannot Use OsvaRen?

OsvaRen is officially approved for use only in adults who are living with chronic renal insufficiency and are undergoing dialysis (haemodialysis or peritoneal dialysis). Eligibility is strictly defined by regulatory documents, primarily focusing on the patient's existing mineral status.

Use of the medicine is contraindicated (must not be used) in patients with specific pre-existing conditions, including elevated blood calcium levels (hypercalcaemia), low blood phosphate levels (hypophosphataemia), or high magnesium levels (hypermagnesaemia). Contraindications also extend to patients with certain diseases that cause hypercalcaemia, such as sarcoidosis or bone metastases, as well as those with known hypersensitivity to the drug's ingredients.

OsvaRen is not recommended for children and adolescents below 18 years of age due to insufficient regulatory data. Use during breastfeeding is also not recommended. For pregnant women, administration is considered conditional: it should only occur if the potential benefits clearly outweigh the risks, and this conditional use necessitates continuous monitoring of serum mineral levels.

Interactions with other medicines and products

The interaction profile of OsvaRen is officially structured around two primary mechanisms: physicochemical binding that reduces drug exposure and pharmacodynamic effects on systemic mineral balance.

To mitigate the reduced bioavailability of other oral medicines, a mandatory timing separation rule is required. All other oral medicinal products must not be taken within the period two hours before and three hours after OsvaRen administration. This restriction applies to many agents, including antibiotics such as Tetracyclines and Quinolones, as well as Bisphosphonates, Digoxin, and oral Iron preparations, which experience decreased systemic exposure due to binding in the gastrointestinal tract.

Pharmacodynamic interactions involve substances that affect calcium or magnesium levels. Vitamin D derivatives and Thiazide Diuretics can increase the risk of hypercalcaemic episodes by increasing calcium absorption or reducing its elimination. This mineral effect leads to severe restrictions: the combination with Cardiac Glycosides or Adrenalin (Epinephrine) is restricted or contraindicated due to the risk of serious arrhythmia when serum calcium is elevated. Additionally, antacids containing calcium or magnesium salts should be avoided to prevent an excessive systemic mineral burden.

OsvaRen's action is defined by intraluminal chemical sequestration within the gastrointestinal tract lumen. The active ingredients, Calcium Acetate and Magnesium Carbonate, rapidly dissociate to release free, reactive cations ( Ca^2+ and Mg^2+). These cations engage in an ionic complexation reaction, chemically binding to dietary phosphate ( PO4^3-) present in the meal.

This binding forms large, insoluble mineral-phosphate complexes that are rendered functionally inert and cannot be absorbed across the intestinal lining. This results in the inhibition of the intestinal phosphate absorption pathway, which is the physiological process the mechanism is designed to modulate. The primary consequence is the physical elimination of the sequestered phosphate via faecal excretion, which subsequently leads to a lowering of the overall serum phosphate concentration in the systemic circulation.

The combined use of Ca^2+ and Mg^2+ provides additive binding capacity to increase the degree of phosphate capture. This dual-cation approach mechanistically supports the goal of effective binding while simultaneously allowing for a lower required dosage of the calcium component, thus resulting in a reduced systemic calcium ion load.

OsvaRen is strictly an oral medicine provided as a film-coated tablet for the management of hyperphosphatemia in adults undergoing dialysis. The administration protocol is structured around a titration-based regimen aimed at achieving the target serum phosphate levels. Treatment typically begins with a standard initial dose of three tablets per day for adults. Following the start of therapy, the dose is adjusted within a maintenance range of 3 to 10 tablets daily, up to a maximum recommended intake of 12 tablets per day. Dose adjustments are based on the individual's response as assessed by serum monitoring.

Timing and Procedural Conditions

A core principle of usage is that the total daily dosage must be divided and consumed only together with the meal to maximize the binding of dietary phosphate in the digestive tract. The tablets must be swallowed whole with some liquid and should not be chewed or crushed. To maintain effectiveness, a time constraint is placed on other oral medicines, which should be taken separated by a window of 2 hours before or 3 hours after the administration of OsvaRen.

If a dose is missed, patients should simply take the next scheduled dose at the usual time and should not attempt to compensate for the missed amount. The medicine is not recommended for use in children or adolescents under 18 years of age.

Research Evidence / Overview of Studies for OsvaRen

---

Evidence for Managing High Phosphate Levels in Dialysis Patients

Research was evaluated in patients undergoing dialysis who have hyperphosphatemia (high phosphate levels), focusing on outcomes related to systemic or functional imbalance. Studies conducted in this area are primarily Randomized Controlled Trials (RCTs), supported by observational studies. RCTs are research settings where participants are assigned by chance to receive the combination or a comparison treatment, allowing researchers to monitor short-term shifts in mineral levels.

These trials were relevant in evidence describing how outcomes related to systemic or functional imbalance—namely serum phosphorus levels—are measured in adult patients (18 years and older) with Chronic Kidney Disease (CKD) who rely on dialysis. The research monitored changes in mineral levels in the study populations over defined time intervals. Studies monitored and reported measured changes in serum phosphorus levels during the study period.

---

Comparison to Other Treatments in Trials

In many research scenarios, studies were designed to compare the combination against other phosphate binders used in clinical practice, such as sevelamer hydrochloride. Research examined whether the measured changes in serum phosphorus were comparable between the two groups. The comparative trials documented patterns where the measured serum phosphorus levels were tracked against the comparator drug over the study period. Research provides context regarding what has been monitored so far. However, comparative evidence is lacking when it comes to long-term outcomes reflecting daily functioning or outcomes linked to major clinical events.

---

What is Still Uncertain About the Research

A primary research limitation is that the studies relied on tracking biomarkers (measurements of mineral levels in the blood) as the main outcome. Findings do not directly describe outcomes related to patient-reported experiences or long-term clinical events, such as cardiovascular complications or survival. Follow-up durations were limited and sample sizes were modest for some analyses, reinforcing that the long-term effects are not fully established. The evidence documents that certain patient groups, such as children and adolescents, have not been sufficiently studied, and findings are uncertain for populations outside of the adult study criteria.

Key Studies & References

1. OsvaRen 435 mg / 235 mg film-coated tablets - Summary of Product Characteristics (SPC)
2. The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film
3. Effect of calcium acetate/magnesium carbonate in the treatment of hyperphosphataemia in dialysis patients in real clinical practice

Common questions about OsvaRen (FAQ)

---

Q: Can OsvaRen be crushed or chewed?

Official product information states that OsvaRen tablets must be swallowed whole with some liquid. Regulatory documents indicate the tablets should not be chewed or crushed. If a tablet is large, the official information advises that it can be broken along the score line immediately before swallowing to avoid the taste of acetic acid.

---

Q: How do I know if the dose is working?

Official information indicates that OsvaRen is used to help control the level of phosphate in the blood. The aim of treatment is to reach target serum phosphate levels. The dose is adjusted based on an individual's response, which is assessed through regular serum monitoring (blood tests).

---

Q: How do I dispose of expired OsvaRen?

To ensure proper disposal, official guidelines advise that unused or expired tablets should not be thrown away in household waste or flushed down a toilet. Individuals can consult with a pharmacist for guidance on local medicine take-back programs.

---

Q: Does OsvaRen have a lactose component?

Based on the official list of ingredients, OsvaRen does not contain lactose. However, it does contain sucrose. Patients with rare hereditary problems, such as fructose intolerance or sucrase-isomaltase insufficiency, may need to discuss this component with a healthcare professional.

---

Q: How long does it take for OsvaRen to start working?

OsvaRen's mechanism involves binding to dietary phosphate in the gastrointestinal tract lumen when the medication is administered with a meal. The effect of this mechanism—the lowering of blood phosphate levels—is tracked through regular serum monitoring during the treatment period to ensure the treatment is optimized.

OsvaRen (calcium acetate and magnesium carbonate) must be stored according to specific regulatory requirements to maintain its stability and ensure safety.

Official Storage Conditions

Requirement	Specification
Temperature	Store at room temperature (e.g., 15–25 °C).
Environment	Must be kept in a dry place.
Packaging	Store in the original container and keep it tightly closed.
Safety	Keep out of the sight and reach of children and pets.

Disposal Instructions

Official guidelines require that unused or expired OsvaRen tablets must not be discarded in household waste or flushed down a toilet. To properly dispose of the medicine, individuals should consult with a pharmacist for guidance on local medicine take-back programs.